Grannus Therapeutics, Inc. — Form D
Grannus Therapeutics, Inc. of INDIANAPOLIS, IN, a company, filed a Form D exempt-offering notice with the SEC on 2024-01-12. The offering totals $800K, of which $800K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-01-12
- Form: D
- Accession: 0001905806-24-000004
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $800K
- Amount sold: $800K
- Minimum investment: $250K
- Investors: 9
- Date of first sale: 2023-11-17
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-502310
Issuer
- Name: Grannus Therapeutics, Inc.
- CIK: 0001905806
- Entity type: Corporation
- Jurisdiction: UNITED STATES
- Incorporated: 2020
- Address: 7210 N. PENNSYLVANIA STREET, INDIANAPOLIS, IN, 46240
- Phone: 3174146205
Officers, directors & promoters (4)
| Name | Role | Location |
|---|
| Brian Blagg | Director | Indianapolis, IN |
| John Foglesong | Director | Indianapolis, IN |
| John Foglesong | Executive Officer | Indianapolis, IN |
| James Thompson | Director | Rushford, MN |
Other filings by this issuer (1)
More